The observation of many cases of mumps in vaccinated children during the 1995-96 period prompted a group of family paediatricians to perform a field evaluation on mumps vaccine efficacy of MMR vaccines. Three-thousands-fifty children in the age range 18 months-7 years and 6 months were enrolled during May and June 1996. Data on 2,099 of them (68.8%) who received one of the three most used MMR vaccine and 646 unvaccinated children (21.2%) were analysed. One-hundred-twenty-four cases of measles (8% in vaccinated children), and 457 cases of mumps (55% in vaccinated children) were reported during a period up to six years since 1990. Vaccine efficacy against measles was 100% for Pluserix®, 95% for Triviraten® (CI 90-98%), and 97% for Morupar® (CI 88-99%). Vaccine efficacy against mumps was 75% for Pluserix® (CI 65-83%), 23% for Triviraten® (CI 6-37%), and 73% for Morupar® (CI 59- 82%). These results confirm the recent observations that the Rubini strain (contained in Triviraten®) has a low efficacy when compared to the Urabe strain (contained in Pluserix® and Morupar®) in preventing mumps. These results also underline that a booster dose for mumps vaccine should be considered in the pre-adolescent age.
|Translated title of the contribution||A field study on vaccine efficacy against mumps of three MMR vaccines|
|Number of pages||7|
|Journal||Rivista Italiana di Pediatria|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health